Long non-coding RNA CRNDE as a potential prognostic biomarker in solid tumors: A meta-analysis

Clin Chim Acta. 2018 Jun:481:99-107. doi: 10.1016/j.cca.2018.02.039. Epub 2018 Mar 1.

Abstract

Background and aim: Long non-coding RNA colorectal neoplasia differentially expressed (CRNDE) has been demonstrated to be highly expressed in many malignant tumors; however, the role of CRNDE in cancer remains undetermined because of limitations in sample size. We conducted a meta-analysis to assess the role of CRNDE in cancer.

Methods: PubMed, Medline, Cochrane Library, Web of Science, EMBASE database, Ovid, Chinese CNKI, and Chinese WanFang database were systematically searched. The relation between CRNDE and the clinicopathological characteristics and prognosis of patients with cancer was determined using pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence interval (CI).

Results: Thirteen studies with 1570 patients were included. The pooled results indicated that high CRNDE expression was related to lymph node metastasis (YES vs. NO: OR = 3.50, 95% CI = [1.05, 8.09]) and TNM stage (I + II vs. III + IV: OR = 0.26, 95% CI = [0.18, 0.37]) but not to gender, tumor size, and differentiation. High CRNDE expression indicated poor overall survival (OS) (HR = 2.06, 95% CI = [1.66, 2.47]). CRNDE could be an independent predictive factor for OS (HR = 1.62, 95% CI = [1.15, 2.08]) in patients with cancer.

Conclusion: Therefore, high CRNDE expression was associated with advanced clinicopathological characteristics, and CRNDE could be used as a reliable prognostic biomarker in human cancer. However, more high-quality studies with a large sample size are needed to support this meta-analysis.

Keywords: LncRNA CRNDE; Meta-analysis; Neoplasm; Prognosis.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Biomarkers, Tumor / genetics*
  • Humans
  • Neoplasms / diagnosis*
  • Neoplasms / genetics*
  • Prognosis
  • RNA, Long Noncoding / genetics*

Substances

  • Biomarkers, Tumor
  • RNA, Long Noncoding